CION Ameerpet
One faulty repair gene raises the risk of two very different cancers. The biology is shared; the management is not. Breast surveillance genuinely works — ovarian surveillance does not — and that asymmetry shapes everything that follows.
It seems arbitrary at first that a single inherited change should raise the risk of cancers in two quite separate places. The explanation is that BRCA1 and BRCA2 are not breast genes or ovarian genes — they are DNA repair genes, and they work in every cell in the body.
Specifically, they repair double-strand breaks in DNA through a process called homologous recombination. When one inherited copy is faulty, that repair runs less reliably everywhere. Breast and ovarian tissue appear particularly vulnerable to the consequences, likely because both are hormonally driven tissues that undergo repeated cycles of cell division across a woman's reproductive life — more division, more opportunity for unrepaired damage to accumulate.
The same mechanism explains the wider pattern families sometimes notice: BRCA2 in particular is associated with increased pancreatic and prostate cancer risk, and with male breast cancer. So when a family history is taken, cancers in male relatives count too, and a father's side that looks unremarkable for breast and ovarian cancer may still be carrying the variant. See the breast cancer hub for the breast side in full.
BRCA1 and BRCA2 fix DNA double-strand breaks in every cell. They are not specific to breast or ovary.
Hormonally driven tissue cycling across reproductive life gives unrepaired damage more chances to accumulate.
BRCA2 also raises pancreatic and prostate risk and male breast cancer — which is why male relatives count in a family history.
The two risks are managed in almost opposite ways, and the reason is the quality of the available screening. For breast cancer, annual MRI alongside mammography from a younger age detects disease early and reliably, so surveillance is a genuine strategy and many carriers manage breast risk that way for years. For ovarian cancer, no surveillance has been shown to reduce mortality — CA-125 and transvaginal ultrasound simply do not catch it early enough. That asymmetry is why the ovarian pathway leans on risk-reducing surgery while the breast pathway can offer a real choice between surveillance and surgery. Source: NCCN Genetic/Familial High-Risk Assessment guidelines.
How breast and ovarian risk are managed differently for the same carrier. The contrast is the point.
| Breast risk | Ovarian risk | |
|---|---|---|
| Lifetime risk, BRCA1 | Roughly 60-70% | Roughly 40-45% |
| Lifetime risk, BRCA2 | Roughly 45-55% | Roughly 15-20% |
| Does surveillance work? | Yes — MRI plus mammography detects early disease. | No — no method has been shown to reduce mortality. |
| Surveillance from | Typically 25-30, depending on family history. | Not recommended as protection; offered only as a stopgap. |
| Risk-reducing surgery | Mastectomy — an option, not the default. | Salpingo-oophorectomy — the principal strategy. |
| Usual timing of surgery | Individual, no age-driven urgency. | 35-40 for BRCA1, 40-45 for BRCA2, after childbearing. |
| Main trade-off | Body image, reconstruction, sensation. | Surgical menopause, brought forward by years. |
*Approximate lifetime estimates from published cohort studies, varying with family history and other factors. They orient a discussion; they do not predict an individual outcome.
The practical difficulty is rarely understanding the biology. It is coordinating two pathways that are often run by teams who never speak to each other.
Enhanced breast screening for BRCA carriers typically means annual MRI alongside mammography, starting considerably earlier than population screening — commonly from around 25 to 30 depending on the gene and family history. MRI is included because it is more sensitive in the dense breast tissue younger women tend to have.
This is a real strategy rather than a holding pattern. Breast cancers found through this surveillance are frequently small and node-negative, which is precisely the position from which treatment works best. Many carriers manage breast risk this way for many years without ever choosing surgery.
There is no ovarian equivalent of that surveillance, and it is important not to pretend otherwise. CA-125 with transvaginal ultrasound has not been shown to reduce ovarian cancer deaths even in high-risk women, because ovarian cancer tends to spread across the peritoneum before it produces a detectable localised abnormality.
That is why risk-reducing salpingo-oophorectomy carries the weight of the ovarian pathway, reducing risk by around eighty per cent. It is also why the timing conversation is more urgent than the breast one — there is no effective safety net while you decide. See risk-reducing surgery.
Many carriers do both, and the order matters. A common pattern is to manage breast risk with surveillance while completing a family, then have risk-reducing salpingo-oophorectomy at the recommended age, and consider risk-reducing mastectomy separately and later if at all.
There is no single correct sequence, and it depends on your gene, your age, your family plans and how you weigh the different trade-offs. What helps is having both mapped out together rather than making each decision in isolation with a different team.
Risk-reducing salpingo-oophorectomy performed before natural menopause reduces exposure to ovarian hormones, and there has been longstanding interest in whether that reduces breast cancer risk too. The evidence is mixed and the effect, if present, is smaller than once believed, so it should not be relied upon as a breast risk strategy.
In the other direction, having a mastectomy does not reduce ovarian risk at all, and it does not change the timing of the ovarian conversation. Each operation addresses its own organ, and it is worth being clear about that rather than assuming one covers both.
Many carriers learn their BRCA status at the point of a breast cancer diagnosis, because testing is now routinely offered then. The result changes decisions immediately: it affects surgical choices between lumpectomy and mastectomy, it informs whether the other breast is treated, and it opens certain systemic treatment options.
It also means the ovarian conversation arrives at an already overwhelming moment. It does not have to be resolved at once — risk-reducing surgery is usually deferred until after breast cancer treatment is complete — but it should be flagged so it does not get lost entirely.
For a carrier without breast cancer who has risk-reducing salpingo-oophorectomy before natural menopause, hormone replacement therapy until around the average age of natural menopause is generally considered appropriate — it replaces hormones the body would still have been making.
Where there is a personal history of breast cancer, particularly hormone-receptor-positive disease, the decision is considerably more complex and individual. This is one of the clearest examples of why the two pathways need to be discussed together rather than in separate clinics.
Any single one of these is a reasonable reason to seek genetic counselling. You do not need the full set.
One woman with both diagnoses is one of the strongest single signals of a BRCA variant in a family.
Breast in one relative and ovarian in another on the same side is the classic hereditary pattern.
Especially in more than one relative, or where one person had cancer in both breasts.
Uncommon and strongly associated with BRCA2. A single case in the family warrants a genetics referral.
Part of the BRCA2 spectrum. Worth mentioning when a family history is taken, since it is often left out.
BRCA passes through fathers equally. Few female relatives on that side can hide a variant entirely.
Ashkenazi Jewish ancestry, and certain other founder populations, carry a higher prevalence of specific BRCA variants — mention it if it applies.
Breast and ovarian risk are frequently managed by different teams who never speak to each other. Having both mapped out together is usually the more useful appointment.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling is delivered in-house at CION for both breast and ovarian hereditary risk.
The commonest practical problem for carriers is fragmentation. Breast risk is managed in one place, ovarian risk in another, genetics somewhere else again, and nobody holds the whole picture. Women end up carrying the coordination themselves, at exactly the point they have least appetite for administration.
Your first consultation at CION is free and runs to about 45 minutes. Genetic counselling and BRCA and HRD testing are delivered in-house, and because CION treats both breast and ovarian cancer, the two risk pathways can be mapped in the same conversation rather than referred between. If you have a result already, bring it; if you are considering testing, bring what you know of the family history from both sides.
Where cancer does develop, CION delivers medical oncology in-house — chemotherapy and maintenance therapy including PARP-inhibitor-class treatment, across 35+ centres in Telangana and Andhra Pradesh. Risk-reducing salpingo-oophorectomy and any gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later.
Breast and ovarian risk mapped together rather than in separate clinics that never speak to each other.
Counselling, testing and the plan that follows delivered by one team rather than across referrals.
Free and unhurried. Long enough to take a proper family history from both sides of the family.
Risk-reducing salpingo-oophorectomy is performed at specialist partner centres and may be billed there.
What a coherent BRCA management plan actually contains. Ask whether yours has all of these.
Which gene, which specific variant, and whether it is definitely pathogenic rather than a variant of uncertain significance. That distinction changes everything: uncertain variants are managed on family history alone, not on the result.
Annual MRI alongside mammography, starting at an age appropriate to your gene and family history — typically from around 25 to 30. Establish who arranges it each year, because surveillance that depends on you remembering to chase it tends to lapse.
Not because a decision is needed today, but because there is no effective surveillance in the meantime and the recommended window is age-defined. Knowing the timeline lets you plan fertility and career around it rather than being surprised by it.
Agree the hormone replacement approach in advance rather than after symptoms begin, and arrange baseline bone density assessment where surgery is planned young. This is the part most often left until too late.
Each sibling and child has a fifty per cent chance of carrying the variant, and cascade testing for a known variant is quick and inexpensive. Genetic counselling includes written material you can pass on without having to explain it yourself. See cascade testing.
Guidance changes, variants are sometimes reclassified, and your own circumstances shift. Staying connected to a genetics service means the plan is updated rather than frozen at whatever was advised years earlier.
Because BRCA1 and BRCA2 are not breast or ovarian genes — they are DNA repair genes that work in every cell in the body. They repair double-strand breaks in DNA through a process called homologous recombination, and when one inherited copy is faulty that repair runs less reliably everywhere. Breast and ovarian tissue appear particularly vulnerable, probably because both are hormonally driven tissues undergoing repeated cycles of cell division across reproductive life, giving unrepaired damage more opportunity to accumulate. The same mechanism explains the raised pancreatic and prostate risk seen with BRCA2.
No. Having one does not cause the other, and many BRCA carriers who develop breast cancer never develop ovarian cancer. What a breast cancer diagnosis in a carrier does mean is that the underlying ovarian risk is still there and still needs managing on its own pathway. In practice the ovarian conversation is usually deferred until breast cancer treatment is complete, which is entirely reasonable — but it should be flagged rather than lost. If you have had breast cancer and have never been offered genetic testing, that is worth raising.
It comes down to how each cancer behaves and how accessible the organ is. The breast is superficial and can be imaged in detail, and breast cancer typically forms a localised lump that MRI and mammography detect while it is small. The ovaries sit deep in the pelvis, and ovarian cancer — particularly the high-grade serous type most associated with BRCA — tends to shed cells across the peritoneal surfaces early, often before any localised abnormality is detectable. Large trials of CA-125 and transvaginal ultrasound have not shown a reduction in ovarian cancer deaths, even in high-risk women.
Possibly to some degree, but the evidence is mixed and the effect appears smaller than was once believed, so it should not be relied on as a breast risk strategy. The theoretical basis is that removing the ovaries before natural menopause reduces lifetime exposure to ovarian hormones. In practice, breast risk management should stand on its own — enhanced surveillance with MRI and mammography, and risk-reducing mastectomy where a woman chooses it. In the other direction, mastectomy does not reduce ovarian risk at all and does not change the timing of the ovarian conversation.
There is no single correct sequence, but a common pattern is to manage breast risk with enhanced surveillance while completing a family, then have risk-reducing salpingo-oophorectomy at the age appropriate to your gene, and consider risk-reducing mastectomy separately and later, if at all. The reasoning is that ovarian risk has no effective safety net while you wait, whereas breast risk does. Your gene, your age, your family plans and how you personally weigh surgical menopause against body image all shift this, which is why it is best mapped out as one conversation rather than two.
This is considerably more complex than for a carrier without breast cancer, and it needs individual specialist advice rather than a general answer. For a woman without a breast cancer history, hormone replacement after risk-reducing salpingo-oophorectomy up to around the average age of natural menopause is generally considered appropriate. Where there is a personal history of breast cancer, particularly hormone-receptor-positive disease, the risks and benefits are weighed quite differently and non-hormonal approaches to managing menopausal symptoms are usually explored first. This is one of the clearest reasons both pathways should be discussed together.
Yes. Genetic counselling and BRCA and HRD testing are delivered in-house at CION, and because CION treats both breast and ovarian cancer, the two risk pathways can be mapped in the same conversation rather than referred between separate services. The first consultation is free and runs to about 45 minutes. Medical oncology — chemotherapy and maintenance therapy including PARP-inhibitor-class treatment — is delivered in-house across more than 35 centres. Risk-reducing salpingo-oophorectomy and any gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there.